Anonymous
Guest
Anonymous
Guest
Shouldn't we be talking about this??????
Forest Laboratories’ (FRX) ceftaroline received a surprisingly unanimous backing Tuesday from an FDA advisory committee, boding well for final approval from the FDA.
The relatively smooth passage also suggests that concerns that the antibiotic might be tripped up by the ongoing debate around the evaluation of such products in the US were overstated. As such, after a pretty torrid time for antibiotic approvals in the US, other companies approaching the FDA with late stage antibiotics could well be taking comfort from ceftaroline’s progress so far.
Forest Laboratories’ (FRX) ceftaroline received a surprisingly unanimous backing Tuesday from an FDA advisory committee, boding well for final approval from the FDA.
The relatively smooth passage also suggests that concerns that the antibiotic might be tripped up by the ongoing debate around the evaluation of such products in the US were overstated. As such, after a pretty torrid time for antibiotic approvals in the US, other companies approaching the FDA with late stage antibiotics could well be taking comfort from ceftaroline’s progress so far.